Multiscale mechanistic modeling in pharmaceutical research and development

Advances in Experimental Medicine and Biology

Volumn 736, Issue , 2012, Pages 543-561

  Kuepfer, Lars ^a   Lippert, Jörg ^a   Eissing, Thomas ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; CELL FUNCTION; CYTOLOGY; DATA PROCESSING; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; EXEMPLARY MULTISCALE MODEL; FINITE ELEMENT ANALYSIS; HUMAN; INTEGRATION; LIPOPHILICITY; MATHEMATICAL MODEL; MEDICAL INFORMATION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MULTISCALE MECHANISTIC MODELING; MULTISCALE MODELING; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STOCHASTIC MODEL; STOICHIOMETRY; TISSUE AND ORGAN SCALE;

COMPUTER SIMULATION; DRUG INDUSTRY; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH;

EID: 84855923550     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7210-1_32     Document Type: Article

References (49)

1. Anderson AR, WeaverAM, Cummings PT, Quaranta V (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905-915 (Pubitemid 44792251)
2. Beal SL, Sheiner V (1994) NONMEM user's guide. NONMEM project group. University of California, San Francisco
3. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, Maiwald T, Timmer J, Klingmuller U (2010) Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 328:1404-1408
4. Briest S, Stearns V (2009) Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 7:185-192
5. Burghaus R, Coboeken K, Gaub T, Kuepfer L, Sensse A, Siegmund HU, Weiss W, Mueck W, Lippert J (2011) Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One 6:e17626
6. Chassagnole C, Jackson RC, Hussain N, Bashir L, Derow C, Savin J, Fell DA (2006) Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. Biosystems 83:91-97 (Pubitemid 43199810)
7. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185 (Pubitemid 36279392)
8. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104:1777-1782 (Pubitemid 46239855)
9. Edginton AN, Willmann S (2006) Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paediatr Perinat Drug Ther 7:146-153 (Pubitemid 46010017)
10. Edginton AN, Willmann S (2008) Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 47:743-752
11. Eissing T, Conzelmann H, Gilles ED, Allgower F, Bullinger E, Scheurich P (2004) Bistability analyses of a caspase activation model for receptor-induced apoptosis. J Biol Chem 279:36892-36897 (Pubitemid 39129038)
12. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund H-U, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J (2011) A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physio 2:4
13. Espie P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB (2009) Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391-407
14. FDA (2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Challenges and Opportunities Report - March 2004
15. Gille C, Bolling C, Hoppe A, Bulik S, Hoffmann S, Hubner K, Karlstadt A, Ganeshan R, KonigM, Rother K,WeidlichM, Behre J, Holzhutter HG (2010) HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology.Mol Syst Biol 6:411
16. Gstaiger M, Aebersold R (2009) Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet 10:617-627
17. Henney AM (2009) Who will take up the gauntlet? Challenges and opportunities for systems biology and drug discovery. EMBO Rep 10(Suppl 1):S9-13
18. Hoehme S, Brulport M, Bauer A, Bedawy E, Schormann W, Hermes M, Puppe V, Gebhardt R, Zellmer S, Schwarz M, Bockamp E, Timmel T, Hengstler JG, Drasdo D (2010) Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci USA 107:10371-10376
19. Hunter PJ, Borg TK (2003) Integration from proteins to organs: the physiome project. Nat Rev Mol Cell Biol 4:237-243 (Pubitemid 36288045)
20. Joyce AR, Palsson BO (2006) The model organism as a system: integrating 'omics' data sets. Nat Rev Mol Cell Biol 7:198-210
21. Kholodenko BN (2006) Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 7:165-176
22. Kuepfer L (2010) Towards whole-body systems physiology. Mol Syst Biol 6:409
23. Kuepfer L, Peter M, Sauer U, Stelling J (2007) Ensemble modeling for analysis of cell signaling dynamics. Nat Biotechnol 25:1001-1006 (Pubitemid 47517639)
24. Lander ES (2011) Initial impact of the sequencing of the human genome. Nature 470:187-197
25. Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ (2011) Navigating the kinome. Nat Chem Biol 7:200-202
26. Nestorov I (2007)Whole-body physiologically based pharmacokinetic models. Exp Opin Drug Metab Toxicol 3:235-249 (Pubitemid 47321518)
27. Noble D (2002) Modeling the heart-from genes to cells to the whole organ. Science 295: 1678-1682 (Pubitemid 34202896)
28. PricewaterhouseCoopers (2007) Which path will you take? Pharma 2020: The vision
29. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V. (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258-264
30. Rao CV, Wolf DM, Arkin AP (2002) Control, exploitation and tolerance of intracellular noise. Nature 420:231-237 (Pubitemid 35340135)
31. Rodriguez B, Burrage K, Gavaghan D, Grau V, Kohl P, Noble D (2010) The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin Pharmacol Ther 88:130-134
32. Rowland M, Tozer TN (2011) Clinical pharmacokinetics and pharmacodynamics - concepts and applications. Lippincott Williams & Williams, Baltimore
33. Savage VM, Deeds EJ, Fontana W (2008) Sizing up allometric scaling theory. PLoS Comput Biol 4:e1000171
34. SchmittW,Willmann S (2005) Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today 2:125-132
35. Schuetz R, Kuepfer L, Sauer U (2007) Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli. Mol Syst Biol 3:119
36. Shlomi T, Cabili MN, Herrgard MJ, Palsson BO, Ruppin E (2008) Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 26:1003-1010
37. Shlomi T, Cabili MN, Ruppin E (2009) Predicting metabolic biomarkers of human inborn errors of metabolism. Mol Syst Biol 5:263
38. Sung JH, Esch MB, Shuler ML (2010) Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Exp Opin Drug Metab Toxicol 6:1063-1081
39. Tawhai MH, Bates JH (2011) Multi-scale lung modeling. J Appl Physiol 110(5):1466-1572
40. Thomas SR (2009) Kidney modeling and systems physiology. Wiley Interdiscip Rev Syst Biol Med 1:172-190
41. Tornoe CW, Agerso H, Jonsson EN, Madsen H, Nielsen HA (2004) Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations. Comput Methods Progr Biomed 76:31-40 (Pubitemid 39094638)
42. van der Graaf PH, Benson N (2011) Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 28(7):1460-1464
43. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122-126 (Pubitemid 27161259)
44. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J (2009) Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 86:634-643
45. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401-431 (Pubitemid 46873033)
46. Willmann S, Lippert J, Schmitt W (2005) From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Exp Opin DrugMetab Toxicol 1:159-168
47. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W (2003) PK-Sim : aphysiologically based pharmacokinetic 'whole-body' model. Biosilico 1:121-124 (Pubitemid 40416764)
48. Willmann S, SchmittW, Keldenich J, Dressman JB (2003) A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 20:1766-1771 (Pubitemid 37449449)
49. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB (2004) A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031 (Pubitemid 38970963)